Doctor profile · Federal record
Dr. John Goetzinger, M.D.
Rheumatology Physician (CMS: Rheumatology) · Student in an Organized Health Care Education/Training Program · Oklahoma City, OK
- NPI 1174979942
- Accepts Medicare
- 10 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
6516 N Olie Ave Ste G
Oklahoma City, OK 731167399
(405) 608-8060
Credentials & registration
- NPI registered
- May 2016 — 10 yrs on file
- Profile last updated
- June 14, 2021
- Year of graduation
- 2016 — 10 yrs since
- Specialty taxonomy
- 207RR0500X — NUCC code
- State license (1)
- Oklahoma #32348
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1174979942. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
16,295
Distinct HCPCS
10
Medicare allowed
$398,160
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 8,850 | 21 | $13 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 3,080 | 28 | $33 | |
J0897 |
Injection, denosumab, 1 mg | 2,940 | 32 | $23 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 289 | 148 | $119 | |
96372 |
Injection of drug or substance under skin or into muscle | 258 | 50 | $13 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 230 | 149 | $83 | |
99204 |
New patient office or other outpatient visit, 45-59 minutes | 179 | 179 | $153 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 107 | 45 | $116 | |
73130 |
X-ray of hand, minimum of 3 views | 103 | 57 | $33 | |
96365 |
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 93 | 25 | $57 |
In context: peer comparison
Among 8 peers in this city , average services per provider: 517. This provider delivers 32× the peer median.Open Payments
Industry payments received
All-time total
$6,654
Transactions
160
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| UCB, Inc. | 17 | $4,042.54 | |
| ABBVIE INC. | 55 | $883.16 | |
| Amgen Inc. | 28 | $446.27 | |
| Janssen Biotech, Inc. | 20 | $345.33 | |
| AstraZeneca Pharmaceuticals LP | 10 | $229.61 | |
| Novartis Pharmaceuticals Corporation | 6 | $113.78 | |
| E.R. Squibb & Sons, L.L.C. | 5 | $99.41 | |
| Sandoz Inc. | 4 | $93.14 | |
| Lilly USA, LLC | 4 | $92.68 | |
| GENZYME CORPORATION | 1 | $78.94 | |
| GlaxoSmithKline, LLC. | 4 | $68.86 | |
| Aurinia Pharma U.S., Inc. | 3 | $54.15 | |
| Mallinckrodt Hospital Products Inc. | 1 | $38.86 | |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21.39 | |
| Genentech USA, Inc. | 1 | $16.34 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
621
Patients
181
Total drug cost
$31,861
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate | Generic | 141 | 64 | $12,607 |
| Methotrexate (Methotrexate Sodium) | Brand | 141 | 56 | $7,491 |
| Prednisone | Generic | 52 | 21 | $536 |
| Folic Acid | Generic | 41 | 17 | $199 |
| Allopurinol | Generic | 36 | 0 | $530 |
| Alendronate Sodium | Generic | 33 | 0 | $323 |
| Leflunomide | Generic | 28 | 11 | $3,241 |
| Duloxetine Hcl | Generic | 25 | 0 | $751 |
| Pregabalin | Generic | 23 | 0 | $1,239 |
| Celecoxib | Generic | 21 | 0 | $1,050 |
Hospital affiliations
Frequently asked questions
What is Dr. John Goetzinger's medical specialty?
Dr. John Goetzinger practices Rheumatology Physician in Oklahoma City, OK.
Where does Dr. John Goetzinger practice?
Dr. John Goetzinger practices at 6516 N Olie Ave Ste G, Oklahoma City, OK 731167399. Office phone: 4056088060.
What is Dr. John Goetzinger's NPI?
Dr. John Goetzinger's National Provider Identifier (NPI) is 1174979942, issued by NPPES.
Does Dr. John Goetzinger accept Medicare assignment?
Yes. Dr. John Goetzinger accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. John Goetzinger commonly perform?
Top Medicare-reported procedures in 2023: Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, infliximab, excludes biosimilar, 10 mg (HCPCS J1745); Injection, denosumab, 1 mg (HCPCS J0897). Source: CMS Medicare Physician & Other Practitioners file.